Skip to main content

Table 1 Baseline characteristics of patients

From: Bortezomib administration is a risk factor associated with the development of tumor lysis syndrome in male patients with multiple myeloma: a retrospective study

  No. of patients (%) or Mean ± SD (n = 210)
Age
 Mean ± SD (years) 67.1 ± 11.1
 ≥ 65 years (%) 132 (62.9)
Sex
 Men 102 (48.6)
Body mass index
 Median (range) 22.4 (15.7–38.3)
ISS stage
 I 39 (18.6)
 II 94 (44.8)
 III 77 (36.7)
Measurable serum M protein
 IgG 121 (57.6)
 IgA 40 (19.1)
 IgD 7 (3.3)
 Light chain 41 (19.5)
 Non-secretory 1 (0.5)
Involved free light chain
Type of free light chain
 kappa 126 (64.6)
 lambda 69 (35.4)
 Unknown 15
Mean ± SD (mg/L)a
 kappa 2494.3 ± 3901.5
 lambda 1629.6 ± 3017.4
Plasma cells in bone marrow (%) b
 Mean ± SD 32.2 ± 22.7
Presence of plasma cell in peripheral blood
 Presence 25 (11.9)
Presence of extramedullary disease c
 Presence 13 (7.4)
Baseline laboratory data (Blood tests)
Lactic dehydrogenase (U/L)
 Mean ± SD 210.8 ± 132.3
Creatinine (mg/dL)
 Mean ± SD 1.19 ± 0.99
Estimated glomerular filtration rate (mL/min/1.73 m2)
 Mean ± SD 61.7 ± 30.3
Uric acid (mg/dL)
 Mean ± SD 5.8 ± 1.8
Potassium (mmol/L)
 Mean ± SD 4.1 ± 0.4
Phosphorus (mg/dL) d
 Mean ± SD 3.6 ± 0.7
β2 microglobulin
 Mean ± SD (μg/mL) 5.7 ± 3.9
Albumin
 Mean ± SD (g/dL) 3.2 ± 0.7
Calcium
 Mean ± SD (mg/dL) 9.1 ± 0.9
Incidence of TLS e
 Laboratory TLS 10 (4.8)
 Clinical TLS 7 (3.3)
  1. ISS International Staging System, TLS Tumor lysis syndrome, SD Standard deviation
  2. aPatients with involved free light chain: n = 88; the analysis for kappa type included only patients with kappa type of involved free light chain (n = 54), and that for lambda type included only patients with lambda type of involved free light chain (n = 34)
  3. bPatients with involved plasma cells in bone marrow: n = 159
  4. cPatients with evaluated extramedullary disease shown by computed tomography: n = 175
  5. dPatients with involved phosphorus: n = 119
  6. eTLS was diagnosed according to the modified criteria of the prior definition during each treatment cycle in the period of primary treatment [2, 3, 7]
\